Patient Selection and Treatment Initiation

• Empiric treatment of hospitalized patients with suspected COVID-19 can be considered pending laboratory confirmation of SARS-CoV-2  infection. 

• Remdesivir can be used at any time after onset of symptoms in hospitalized patients.  

• Determine eGFR in all patients before starting Remdesivir and monitor while receiving Remdesivir as clinically appropriate. 

• Perform hepatic laboratory testing in all patients before starting Remdesivir and during treatment as clinically appropriate. 

• Determine prothrombin time in all patients before starting Remdesivir and monitor during treatment as clinically appropriate

Use of Remdesivir is confined to healthcare facilities in which patients can be monitored closely.

The recommended dosage of Remdesivir in patients 12 years of age and older and weighing at least 40 kg is :

• Day 1 – single loading dose of Remdesivir 200 mg given by intravenous infusion. 

• Day 2 onwards – 100 mg given once daily by intravenous infusion.

The total duration of treatment should be at least 5 days and not more than 10 days.  For patients requiring invasive mechanical ventilation and/or ECMO, total treatment duration is 10 days.  For patients not requiring invasive mechanical ventilation and/or ECMO, total treatment duration is 5 days. If a patient does not demonstrate  clinical improvement, treatment may be extended for up to 5 additional days (i.e., up to a total of 10 days).  Administer Remdesivir via IV infusion over 30 to 120 minutes